Dorian Haskard was an undergraduate at Oxford University before moving to The Middlesex Hospital Medical School and subsequently into a range of clinical and research posts in London and the US. In 1987 he was awarded a Wellcome Trust Senior Clinical Fellowship at UMDS, Guy's Hospital. Following this he was appointed to Senior Clinical Lectureship at the Royal Postgraduate Medical School, Hammersmith Hospital, being promoted to Reader and then to Professor in 1995.
Professor Haskard has previously held the following leadership positions at Imperial College: British Heart Foundation Sir John McMichael Chair of Cardiovascular Medicine (1995-2016); Head of the Vascular Sciences Section within the National Heart and Lung Institute (2014-2017); Head of Division of Immunology and Inflammation in the Department of Medicine (2010-2017); and Head of the Division of Clinical Cardiovascular Science (2017-2018).
Professor Haskard has given numerous prestigious national and international lectures and is member of a number of learned societies and funding charities. Notably he was Chairman of the Arthritis Research Campaign Fellowship Committee (2000-2005) and Chairman of the British Atherosclerosis Society (2008-2010). He is President of the International Society for Behçet’s Disease (President 2016-2010), and serves on the National Anti-Doping Panel (NADP).
He has directly supervised 7 post-docs; 45 completed PhD students and many MSc, MRes and BSc students have performed projects within his personal research group at Imperial College.
The goal of Professor Haskard's research has been to achieve a greater understanding of the pathophysiology of inflammatory responses affecting the vascular system, with a view eventually to achieving more specific clinical diagnostic tests and therapies. Current work focuses on two main areas in relation to the biology of vascular inflammation and atherosclerosis: (i) mechanisms of macrophage and endothelial cell gene expression, with an emphasis on post-transcriptional RNA regulation, and (ii) the role of antibodies and complement.
et al., 2018, IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3), Ebiomedicine, Vol:36, ISSN:2352-3964, Pages:63-72
Hartley A, Haskard D, Khamis R, 2018, Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy., Trends Cardiovasc Med
et al., 2018, Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling, Scientific Reports, Vol:8, ISSN:2045-2322
Pandey SS, Haskard DO, Khamis RY, 2017, Developing a Strategy for Interventional Molecular Imaging of Oxidized Low-Density Lipoprotein in Atherosclerosis, Molecular Imaging, Vol:16, ISSN:1536-0121
et al., 2017, SELECTIVE ACTIVATION OF AN AMPK-CREB-NRF2-DEPENDENT PATHWAY BY CELECOXIB INDUCES VASCULOPROTECTIVE GENES AND MITIGATES AGAINST CARDIOVASCULAR RISK, Annual European Congress of Rheumatology, BMJ PUBLISHING GROUP, Pages:219-219, ISSN:0003-4967